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Update on Development of a Tranquilizer Trap Device
Peter J. Savarie
Kathleen A. Fagerstone
Edward W. Schafer) Jr.
U. S. D. A. Denver Wildlife Research Center
The foothold trap is an important tool that is
used by the U.S. Department of Agriculture
Animal Damage Control (ADC) program to
capture coyotes (Canis latrans) that are
causing livestock depredations. In FY 1990
and FY 1991 the ADC program trapped
17,732 and 15,805 coyotes, respectively
(USDA 1991;1992). Foothold traps can
cause trauma and injury to feet and legs
(Englund 1982; Linhart et al. 1986; Olsen et
al. 1986, 1988; Onderka et al. 1990, Tullar
1984) and Onderka et al. (1990) observed
oral injuries such as broken teeth, and
tongue and gum lacerations in captured
animals. The ADC program and other
organizations such as the U. S. Technical
Advisory Group for Humane Trap Standards
(Linhart 1990), are investigating means of
reducing injuries to animals caught in traps.
Two approaches to reduce injuries, trap
modification and the use of a tranquilizer,
have been investigated and previously tested
in the field. Most of the studies have focused
upon trap modifications. Several studies
have evaluated the padded jaw trap (Linhart
et al. 1986; 1988; Linhart and Dasch 1992;
Olsen et al. 1986; Onderka et al. 1990;
Tullar 1984). These studies show that
padded foothold traps reduce, but do not
eliminate injury to captured animals.
The use of a tranquilizer device attached to a
foothold trap jaw was described by Balser in
1965. This research showed that the use
of the tranquilizer, diazepam, reduced foot
and leg injuries, struggling, aggression,
escapes, and eased the release of nontarget
species such as dogs (Canis familiaris).
Diazepam is a U. S. Department of Justice,
Drug Enforcement Administration (DEA)
controlled substance (Seal and Kreeger 1987)
and it never became authorized as a
tranquilizer for traps. Savarie and Roberts
(1979) evaluated several other tranquilizers
under laboratory conditions as possible
replacements for diazepam; their tests did not
use foothold traps but instead used behavioral
observations to determine Central Nervous
System depression. Favorable results were
obtained with propiopromazine
hydrochloride (HCl), and it was later
evaluated with foothold traps under field
conditions by Linhart et al. (1981). Linhart's
study tested propiopromazine HCl with four
different types of delivery devices; with each
type, 75 to 90% of animals had little or no
foot damage at a 24-hr check period as
compared to only 14% with little or no
damage for controls in which the tranquilizer
was not used. These investigators noted that
additional studies were needed for
development of a tranquilizer trap device.
However, studies were discontinued and
research efforts were directed toward
evaluation of the padded jaw trap.
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In recent years there has been renewed
interest in the tranquilizer trap device by the
ADC program. Zemlicka and Bruce (1991)
conducted tests with pen-reared coyotes
under laboratory conditions to evaluate
delivery systems and formulations of
tranquilizer trap devices containing
propiomazine HC1. ?heir results were
encouraging but they recommended further
field test evaluations before final
recommendations could be made on the
most effective tranquilizer trap devices.
This paper will give a general outline of the
process that the Denver Wildlife Research
Center (DWRC) proposes to initiate for the
development of a tranquilizer for use in a
trap device. The tranquilizer would be
classified as a veterinary product regulated
by the Food and Drug Administration (FDA)
and must comply with the Federal Food,
Drug and Cosmetic Act as described in 21
Code of Federal Regulations (CFR) 512. An
Investigational New Animal Drug
Application (INADA) is required to be filed
as the initial step in gaining approval from
the FDA to use an animal drug. This is the
beginning of a lengthy process which
includes dose titration studies and clinical
trials to insure product efficacy and safety
standards as established by FDA. FDA
procedures are similar to those of the
Environmental Protection Agency (EPA);
however, the burden of proof for drug quality
is on the drug manufacturer, not on the
registrant and the FDA generally does not
require environmental effects and fate data.
Upon submission of a New Animal Drug
Application (NADA) and approval, the drug
would become legally available for use for
designated wildlife species by authorized
wildlife professionals. Described below are 8
phases of research effort that we anticipate
will be required to develop a tranquilizer for
the trap device.
Phase 1: Selection of a Suitable Drug
Although propiopromazine HCl has proved
to be effective in field trials, this drug may no
longer be available because of lack of a
commercial demand. Also, there have been
many tranquilizers developed in the past 10
to 15 years that may have better potential.
Literature reviews will be conducted and
contacts will be established with
pharmaceutical companies in an attempt to
find a suitable chemical. A suitable chemical
includes the following factors: high potency,
high margin of safety (ratio of lethal and
effective dose), good stability, continued
drug availability, patent status that will allow
use without excessive cost, location of a
company willing to supply the drug,
availability of analytical methodology, and
minimal hazards to nontarget species (i.e.,
dose that is lethal to nontargets should be
higher than dose that would tranquilize target
animal). Drugs that will be reviewed include:
1) First and second generation tranquilizers
that have been available for over 30 years.
Advantages would be that they are relatively
inexpensive, and generally have no patent
protection. However, many of these
tranquilizers have a low level of biological
activity, and may not be available from
producers for more than 5 to 10 years; 2)
Third and fourth generation tranquilizers
have been available for 20 years or less.
These tranquilizers are moderately expensive
because many use or manufacturing patents
are still in effect. They have a moderate level
of biological activity, but would probably be
available for 10 years or longer; and 3) Fifth
and sixth generation tranquilizers are recently
developed or experimental chemicals. These
tranquilizers
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are very expensive because of tight producer
control, and long-term patent coverage.
However, advantages would be a high level
of biological activity (very low dosage rate),
and they should be available for at least 10
to 20 years.
From the Phase I review, a decision-making
matrix will be developed incorporating
estimates for each candidate drug for cost
per tranquilizer device, development and
authorization costs, and use restrictions. At
this point, a decision will be made regarding
the candidate drugs of choice for efficacy
and potential nontarget testing.
Phase 2: Testing of Candidate Drugs
To select the best possible candidates) for
field evaluations, a limited number of drugs
selected from the Phase I evaluation would
be tested for efficacy on captive coyotes
under laboratory conditions by procedures
similar to those described by Savarie and
Roberts (1979). Protocols for these dose
titration tests would have to be approved by
FDA.
Phase 3: Tranquilizer Delivery System and
Analytical Methodology
Research will commence on a delivery
device for the drugs) of choice. As the
delivery device is developed, an analytical
assay method for the use formulations) will
have to be developed.
Phase 4: Summary of Existing
Information, Completion and
Submission of NADA, and
Request for Expedited Review
The IIv'ADA will be prepared (with all
required supportive documentation) and
submitted to FDA. A number of the FDA
requirements will have to be addressed at
this time, including location of a Source
Manufacturer, and development of labeling
and files to track the chemical. Telephone
consultations and visits to FDA will be
required. A request for Expedited Review,
which limits the amount of time FDA may
take to respond, may also be developed and
submitted.
Phase 5: Design of protocol:, sod
Continued Research on Delivery
System and Analytical
Methodology
Protocols will have to be submitted to FDA
for clinical trials of the tranquilizer trap
device to support safety and efficacy claims.
Negotiation and work sessions with FDA
will occur during this phase. Research on a
delivery system and validation of an
analytical method for the formulation will
continue. Nontarget hazards may need to be
addressed, depending upon the projected use
pattern.
Phase 6: Clinical T»als
Laboratory and field clinical trials will be
conducted according to FDA approved
protocols and with Quality Assurance
monitoring. Data will be analyzed and
summarized.
Phase 7: Completion and Submission of
NADA and Expedited Review
A NADA will be submitted upon completion
of summary of data supporting safety and
efficacy claims. Among the requirements of
21 CFR 514, the following items will be
addressed in the NADA: 1) Labeling, 2)
Manufacturing Methods, Facilities and
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Controls, 3) Analytical Methods for
Residues, 4) Evidence to Establish Safety
and Effectiveness, and 5) Environmental
Impact Analysis (EIA).
Phase 8: Finalization of NADA and
Submission of Documents for
FDA Approval
Following negotiation with FDA regarding
the NADA, any further data requirements
will be met and a final revised report will be
submitted to FDA. At this time, a Freedom
of Information Statement and a final EIA
will be submitted. In addition, it will
probably be necessary during this phase to
prepare an Environmental Assessment in
compliance with the National Environmental
Policy Act.
The total projected time and cost for
development of a tranquilizer trap device is
4.5 years and $500,000 to $1,000,000.
Timing for some of the phases can overlap,
and will involve the interaction of several
disciplines.
Summary
The ADC program is concerned about
animal welfare and the humaneness of the
methods it uses in its control and extension
programs. A tranquilizer trap device has been
proposed for attachment to foothold traps,
snares and live traps to tranquilize animals to
reduce the possibility of trap injuries. The
device will be developed first for use on
coyotes and subsequently for possible use on
other species. A synopsis for development of
a tranquilizer trap device is described that
includes selection of a suitable drug,
laboratory testing, development of
appropriate applications for submission to
the FDA, performance of field
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padded steel foothold traps for capturing
coyotes. Wild. Soc. Bull. 14:212-218.
_ F. S. Blom, G. J. Dash, R. M.
Engeman, and G. H. Olsen. 1988. Field
evaluation of padded jaw coyote traps:
effectiveness and foot injury. Pros. Vertebr.
Pest Conf. 13:226-229.
1990. The current status of
International Trap Standards. Pros. Seventh
Midwest Third southeast Furbearer
Workshop (February 27-March 2, 1989,
Potosi, MO) p.12.
.and G. J. Dasch. 1992. Improved
performance of padded jaw trabs for
capturing coyotes. Wild]. Soc. Bull. 20:6366.
207
safety and efficacy trials, and approval of a
NADA by the FDA.
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